{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:24:40Z","timestamp":1765545880210},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T00:00:00Z","timestamp":1389052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1038\/tpj.2013.46","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T11:04:25Z","timestamp":1389092665000},"page":"316-321","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Building pharmacogenetics into a pharmacovigilance program in Singapore: using serious skin rash as a pilot study"],"prefix":"10.1038","volume":"14","author":[{"given":"D S L","family":"Toh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L L","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D C W","family":"Aw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S H","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Thirumoorthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H Y","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y K","family":"Tay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S K","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lateef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y Y","family":"Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y C","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Loke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C L","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E S C","family":"Koay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E C","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E J D","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"key":"BFtpj201346_CR1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/BF03262002","volume":"35","author":"L Aagaard","year":"2012","unstructured":"Aagaard L, Strandell J, Melskens L, Petersen PSG, Holme Hansen E . Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase\u2122. Drug Saf 2012; 35: 1171\u20131182.","journal-title":"Drug Saf"},{"key":"BFtpj201346_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/428486a","volume":"428","author":"W-H Chung","year":"2004","unstructured":"Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C et al. A marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.","journal-title":"Nature"},{"key":"BFtpj201346_CR3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","volume":"6","author":"C Lonjou","year":"2006","unstructured":"Lonjou C, Thomas L, Borot N, Ledger N, De Toma C, Lelouet H et al. A marker for Stevens-Johnson syndrome ethnicity matters. Pharmacogenomics J 2006; 6: 265\u2013268.","journal-title":"Pharmacogenomics J"},{"key":"BFtpj201346_CR4","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","volume":"48","author":"CBL Man","year":"2007","unstructured":"Man CBL, Kwan P, Baum L, Yu E, Lau KM, Cheng ASH et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015\u20131018.","journal-title":"Epilepsia"},{"key":"BFtpj201346_CR5","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","volume":"49","author":"C Locharernkul","year":"2008","unstructured":"Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T, Tongkobpetch S et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49: 2087\u20132091.","journal-title":"Epilepsia"},{"key":"BFtpj201346_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ajo.2006.09.029","volume":"143","author":"M Ueta","year":"2007","unstructured":"Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S . Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143: 367\u2013368.","journal-title":"Am J Ophthalmol"},{"key":"BFtpj201346_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/clpt.2011.79","volume":"89","author":"M Pirmohamed","year":"2011","unstructured":"Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E et al. Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 2011; 89: 896\u2013901.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201346_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","volume":"16","author":"S-I Hung","year":"2006","unstructured":"Hung S-I, Chung W-H, Jee S-H, Chen W-C, Chang Y-T, Lee W-R et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297\u2013306.","journal-title":"Pharmacogenet Genomics"},{"key":"BFtpj201346_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1034\/j.1399-0039.1999.530308.x","volume":"53","author":"S Pozzi","year":"1999","unstructured":"Pozzi S, Longo A, Ferrara GB . HLA-B locus sequence-based typing. Tissue Antigens 1999; 53: 275\u2013281.","journal-title":"Tissue Antigens"},{"key":"BFtpj201346_CR10","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood.V86.4.1606.bloodjournal8641606","volume":"86","author":"EW Petersdorf","year":"1995","unstructured":"Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995; 86: 1606\u20131613.","journal-title":"Blood"},{"key":"BFtpj201346_CR11","first-page":"TMI14.A12","volume-title":"IHWG Technical Manual Genomic Analysis of the Human MHC DNA-Based Typing for HLA Alleles and Linked Polymorphism","author":"AW van der Zwan","year":"2000","unstructured":"van der Zwan AW, Griffith B, Rozemuller E In: Tilanus MG, Hansen JA, Hurley C, (eds). IHWG Technical Manual Genomic Analysis of the Human MHC DNA-Based Typing for HLA Alleles and Linked Polymorphism. International Histocompatibility Working Group: Seattle, 2000, pp TMI14.A12\u201314."},{"key":"BFtpj201346_CR12","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","volume":"364","author":"M McCormack","year":"2011","unstructured":"McCormack M, Alfirevic A, Bourgeois S, Farrell JJ, Kasperavi\u010di\u016bt\u0117 D, Carrington M et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134\u20131143.","journal-title":"N Engl J Med"},{"key":"BFtpj201346_CR13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","volume":"20","author":"T Ozeki","year":"2011","unstructured":"Ozeki T, Mushiroda T, Yowang A, Takahashi A, Kubo M, Shirakata Y et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20: 1034\u20131041.","journal-title":"Hum Mol Genet"},{"key":"BFtpj201346_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/hdy.2013.27","volume":"111","author":"TH Lam","year":"2013","unstructured":"Lam TH, Shen MX, Chia JM, Chan SH, Ren EC . Population-specific recombination sites within the human MHC region. Heredity 2013; 111: 131\u2013138.","journal-title":"Heredity"},{"key":"BFtpj201346_CR15","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","volume":"279","author":"J Lazarou","year":"1998","unstructured":"Lazarou J, Pomeranz BH, Corey PN . Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200\u20131205.","journal-title":"JAMA"},{"key":"BFtpj201346_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15\u201319.","journal-title":"BMJ"},{"key":"BFtpj201346_CR17","doi-asserted-by":"publisher","first-page":"e4439","DOI":"10.1371\/journal.pone.0004439","volume":"4","author":"EC Davies","year":"2009","unstructured":"Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M . Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009; 4: e4439.","journal-title":"PLoS One"},{"key":"BFtpj201346_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4103\/0378-6323.57718","volume":"75","author":"DM Dave","year":"2009","unstructured":"Dave DM, Goyal RK, Joshi CG, Mehta TY, Mittal B, Patel DB . Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75: 579\u2013582.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"BFtpj201346_CR19","first-page":"290","volume":"29","author":"SM Then","year":"2011","unstructured":"Then SM, Rani Z, Raymond A, Ratnaningrum S, Jamal R . Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients. Asia Pac J Allergy Immunol 2011; 29: 290\u2013293.","journal-title":"Asia Pac J Allergy Immunol"},{"key":"BFtpj201346_CR20","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/clpt.2012.189","volume":"92","author":"VL Yip","year":"2012","unstructured":"Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA . Genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012; 92: 757\u2013765.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtpj201346_CR21","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","volume":"128","author":"T-M Ko","year":"2011","unstructured":"Ko T-M, Chung W-H, Wei C-Y, Shih H-Y, Chen J-K, Lin C-H et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128: 1266\u20131276.","journal-title":"J Allergy Clin Immunol"},{"key":"BFtpj201346_CR22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1212\/WNL.0b013e31826aac73","volume":"79","author":"D Dong","year":"2012","unstructured":"Dong D, Sung C, Finkelstein EA . Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology 2012; 79: 1259\u20131267.","journal-title":"Neurology"},{"key":"BFtpj201346_CR23","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1111\/j.1528-1167.2006.00633.x","volume":"47","author":"WH Theodore","year":"2006","unstructured":"Theodore WH, Spencer SS, Wiebe S, Langfitt JT, Ali A, Shafer PO et al. Epilepsy in North America: a report prepared under the auspices of the global campaign against epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia 2006; 47: 1700\u20131722.","journal-title":"Epilepsia"},{"key":"BFtpj201346_CR24","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/pds.1772","volume":"18","author":"B Carleton","year":"2009","unstructured":"Carleton B, Poole R, Smith M, Leeder J, Ghannadan R, Ross C et al. Adverse drug reaction active surveillance: developing a national network in Canada\u2019s children\u2019s hospitals. Pharmacoepidemol Drug Saf 2009; 18: 713\u2013721.","journal-title":"Pharmacoepidemol Drug Saf"},{"key":"BFtpj201346_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2217\/14622416.7.4.633","volume":"7","author":"M Molokhia","year":"2006","unstructured":"Molokhia M, McKeigue P . EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 2006; 7: 633\u2013638.","journal-title":"Pharmacogenomics"},{"key":"BFtpj201346_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ddtec.2007.11.003","volume":"4","author":"AL Holden","year":"2007","unstructured":"Holden AL . The innovative use of a large-scale industry biomedical consortia to research the genetic basis of drug induced serious adverse events. Drug Discov Today 2007; 4: 75\u201385.","journal-title":"Drug Discov Today"},{"key":"BFtpj201346_CR27","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.drudis.2011.08.006","volume":"16","author":"M Pirmohamed","year":"2011","unstructured":"Pirmohamed M . Pharmacogenetics: past, present and future. Drug Discov Today 2011; 16: 852\u2013861.","journal-title":"Drug Discov Today"},{"key":"BFtpj201346_CR28","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","volume":"9","author":"N Kaniwa","year":"2008","unstructured":"Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9: 1617\u20131622.","journal-title":"Pharmacogenomics"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tpj201346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201346","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tpj201346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T10:03:38Z","timestamp":1647943418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tpj201346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,7]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["BFtpj201346"],"URL":"https:\/\/doi.org\/10.1038\/tpj.2013.46","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,7]]},"assertion":[{"value":"12 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}